Document is current
Any future updates will be listed below
-
Authors
Karjosukarso, Dyah W. https://orcid.org/0000-0002-0881-9905
Bukkems, Femke
Duijkers, Lonneke
Tomkiewicz, Tomasz Z.
Kiefmann, Julia
Sarlea, Andrei https://orcid.org/0000-0002-7008-1307
Bervoets, Sander https://orcid.org/0009-0004-3958-7520
Vázquez-Domínguez, Irene https://orcid.org/0000-0001-9753-521X
Molday, Laurie L.
Molday, Robert S.
Netea, Mihai G. https://orcid.org/0000-0003-2421-6052
Hoyng, Carel B.
Garanto, Alejandro
Collin, Rob W. J. https://orcid.org/0000-0003-4347-6503
-
Funding
Funding for this research was provided by:
Foundation Fighting Blindness (TA-GT-0521-0799-RAD-TRAP)
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 13 December 2024
First Online: 21 January 2025
Competing interests
: R.W.J.C. is the Chief Executive Officer (interim) of Astherna B.V. C.B.H. is Senior Clinical Advisor of Astherna B.V. F.B. is employed in Astherna B.V. from September 1st 2023. R.W.J.C. and A.G. are inventors on several filed patents describing the use of antisense oligonucleotides (WO2013036105A1, WO2018109011A1, WO2020015959A1, WO2020115106A1, WO2021023863A1) to treat inherited retinal diseases, including Stargardt disease. These patents have been licensed by Radboudumc to Astherna B.V. M.G.N. is a scientific founder of TTxD, Lemba and Biotrip (not related to the current study).
